Beam Therapeutics Inc. announced ongoing progress in its precision genetic medicines pipeline, highlighting updates in its liver-targeted genetic disease and hematology programs. The company reported an estimated $1.25 billion in cash, cash equivalents, and marketable securities as of December 31, 2025. This figure includes $255.1 million received from the acquisition of Orbital Therapeutics by Bristol-Myers Squibb, with the potential for up to an additional $26.3 million pending escrow releases. Beam stated its cash position is expected to fund operating expenses and capital expenditures into 2029, supporting the anticipated launch of risto-cel in sickle cell disease (SCD) and the execution of the BEAM-302 pivotal development plan in alpha-1 antitrypsin deficiency (AATD). The company also noted plans for a potential biologics license application (BLA) submission for risto-cel by the end of 2026. These financial results are preliminary, unaudited, and subject to finalization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-009722), on January 12, 2026, and is solely responsible for the information contained therein.